|
|
 |
 |
|
|
Celtic Pharma is a global private equity firm focused on the biotechnology and pharmaceutical industries. Celtic Pharma was founded by Stephen Evans-Freke and John Mayo, CBE and is based in Bermuda with offices in London and New York. Celtic Pharma acquires late stage pharmaceutical programs and drives these programs through the final stages of regulatory approval. Celtic Pharma's aim is to bridge the gap between the established pharmaceutical companies' new product pipeline crisis and the biotech industry's capital drought. For further information, please visit Celtic Pharma's website at www.celticpharma.com.
Neurobiological Technologies, Inc. (NTI) (Nasdaq: NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer.
The company receives royalties from sales of Namenda (Memantine), which was approved by the FDA in late 2003, for use in patients with Alzheimer's disease. Namenda is marketed in the United States by Forest Laboratories, Inc. and overseas by H. Lundbeck A|S and Merz Pharmaceuticals GmbH.
The company is in the process of developing two additional late-stage compounds; Viprinex™ (Ancrod), for ischemic stroke, and XERECEPT, for peritumoral brain edema associated with brain cancer. XERECEPT is currently under clinical development in the United States and Canada with the collaboration of Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) and NTI. For more information please go to www.ntii.com.
|
|
|
|
|
